<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri","sans-serif";
color:windowtext;}
p.DataField11pt, li.DataField11pt, div.DataField11pt
{mso-style-name:"Data Field 11pt";
margin:0in;
margin-bottom:.0001pt;
line-height:15.0pt;
mso-line-height-rule:exactly;
text-autospace:none;
font-size:11.0pt;
font-family:"Arial","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><b>ChBE Dept. Seminar<br>10:30am-11:30am, Friday, November 15, 2013<br>Rm W122</b><o:p></o:p></p><p class=MsoNormal align=center style='text-align:center'><b>“</b>Design of Immunotherapeutics to Prevent & Treat Infectious Diseases<b>”</b><o:p></o:p></p><p class=MsoNormal align=center style='text-align:center'>Jennifer Maynard<o:p></o:p></p><p class=MsoNormal align=center style='text-align:center'>University of Texas at Austin<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=DataField11pt style='margin-bottom:6.0pt;text-align:justify;line-height:normal'><b><u><span style='font-size:12.0pt;font-family:"Times New Roman","serif"'>ABSTRACT:</span></u></b><span style='font-size:12.0pt;font-family:"Times New Roman","serif"'> </span><span style='font-family:"Calibri","sans-serif";color:black'>The protein engineering toolbox has been used extensively to develop designer enzymes and antibodies meeting pre-determined biochemical/ biophysical specifications to maximize their industrial or clinical efficacy. However, protein engineering has seen only minor applications in development of therapeutics – including prophylactic vaccines and passive immunization – to prevent infectious diseases. Here, we report our progress in design of antigens and instant immune responses which hinges upon knowledge of protein structure-function relationships. <o:p></o:p></span></p><p class=DataField11pt style='margin-bottom:6.0pt;text-align:justify;line-height:normal'><span style='font-family:"Calibri","sans-serif";color:black'>In spite of near-universal vaccination, whooping cough remains a significant public health problem with no specific therapy for established disease. Indeed, rates have been rising dramatically since the full introduction of the acellular vaccine. To understand this vaccine’s limitations and contribute to design of the third generation vaccines, we have examined a number of relevant neutralizing epitopes. We have identified the location of a potently neutralizing epitope on the pertussis toxin and the mechanism by which antibodies binding this epitope can block toxin function. We further show that this epitope is damaged by the vaccine formulation process and that immunization with the current vaccine results in a low level of antibodies binding this epitope relative to natural infection. <o:p></o:p></span></p><p class=DataField11pt style='margin-bottom:6.0pt;text-align:justify;line-height:normal'><span style='font-family:"Calibri","sans-serif";color:black'>The adenylate cyclase toxin (ACT) is an important virulence factor not currently included in any vaccine formulation, with poorly characterized protective epitopes. To better define these, we expressed full-length and individual ACT domains in <i>E. coli </i>and analyzed murine ACT-specific antibody repertoires. Of the four domains, one appears to be a “decoy domain,” dominating the antibody response, yet producing non-neutralizing antibodies. In contrast, fewer antibodies were identified binding epitopes in other domains but several of these potently neutralized ACT’s adenylate cyclase and hemolytic activities. Immunization with just this domain produces a robust neutralizing antibody response, suggesting it is a candidate for inclusion in future vaccines. <o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p></div></body></html>